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radiation oncology centers worldwide. We now know that 
these side effects can most often be attributed to the use of 
outdated RT techniques. As treatment techniques started to 
improve, enabling to limit the dose to the organs at risk, 
prospective trials were initiated to evaluate the contribution 
of lymph node treatment to overall outcome for early stage 
breast cancer patients. The results of several studies were 
presented over the last couple of years. They demonstrate 
that an increased disease-free survival rate following a 
decrease of the risk of distant metastases can be obtained in 
patients with risk factors, including those with involvement 
of the axillary lymph nodes and those with a centrally or 
medially located primary tumour. Moreover, a trend towards 
an improved overall and (statistically significant for some of 
the studies) breast cancer specific survival was 
demonstrated. No increase was seen in the other causes of 
death and, at a median follow-up of around 10 years, no 
significant or clinical relevant increased toxicity was found, 
apart from a slight increase in the risk for pulmonary toxicity. 
The concept of “any recurrences”, introduced by the EBCTCG 
in 2011, as important endpoint of the evaluation of the effect 
of all types of treatments (including locoregional ones such as 
surgery and RT) fits much better to the interpretation of the 
recently presented results. In this era of earlier diagnosis and 
more widespread use of adjuvant systemic treatments 
leading to a 10-year overall survival exceeding 80%, clinically 
detectable locoregional recurrences as a separate endpoint 
might indeed be considered as less relevant. Firstly, the 
patient will be affected heavily by any type of recurrence 
and secondly because of the complex interaction between 
the efficacy of systemic treatments with the influence of 
loco-regional treatments on overall survival. By merely 
focusing on locoregional control, we risk to neglect that once 
distant metastases are found no further efforts are 
undertaken to detect locoregional recurrences. 
By eliminating microscopically non-detectable cancer cells in 
the lymph nodes with RT, the risk of secondary metastasizing 
of those cells and thereby ultimately the overall risk of 
recurrence of the breast cancer will be reduced. This is in 
line with the findings of the EORTC trial in which a trend was 
seen towards more benefit for patients who where treated 
with both hormonal treatment and chemotherapy and less 
benefit for the small group of patients with 10 or more 
involved axillary lymph nodes: patients with a better 
prognosis (lower risk factors and/or better systemic therapy) 
experience more benefit from locoregional treatments. With 
modern RT techniques, the benefits of optimizing 
locoregional control will likely not be counterbalanced by 
side effects including late cardiovascular mortality. 
Moreover, the new ESTRO guidelines for target volume 
delineation clearly reduce the size of the target volumes 
while simultaneously considering the regional lymph nodes 
even more than before as a whole. We also expect that the 
real benefit of loco-regional RT used to be diluted in the past 
(including the recently presented trials) by suboptimal dose 
coverage of the target volumes. Therefore, we expect that 
with contemporary RT techniques and appropriate target 
volume delineation, not only a significant reduction of the 
dose to the organs at risk but also a much better coverage of 
especially the internal mammary lymph nodes is achievable, 
which is likely to result in a further improvement of the 
benefit of locoregional RT for patients with early stage breast 
cancer that have a risk for bearing microscopical tumor 
deposits in the regional lymph nodes. 
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The quality of radiotherapeutic approaches to treating 
locoregional lymph nodes in breast cancer is improving. This 
talk will review the latest evidence pertaining to each aspect 
of the planning and treatment pathway in order to inform 
best practice. Recently published atlases capable of 
improving consistency in outlining target and non-target 
volumes will be reviewed. Using data relating outcomes to 
dosimetry, we will then review the evidence base for target 
and non-target tissue dose constraints and objectives. 
Different radiotherapeutic approaches including breath-hold, 
volumetric-modulated arc therapy, and proton beam therapy 
will be compared in terms of dosimetry and resource 
implications. Potential efficiency savings in the treatment 
pathway will also be discussed together with a review of the 
possible impact of bluer-sky technologies. 
 
Symposium: Assessment and management of rectal 
morbidity  
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As shown in randomized studies, radiotherapy has a critical 
role when we cure prostate cancer by using multimodal 
treatment strategies. We frequently use radiotherapy to cure 
gynecological cancer. Both Intensity-Modulated Radiation 
Therapy and Volumetric Modulated Arc Therapy have the 
potential to drastically increase the ratio between 
possibilities for cure and risk of late effects. Still, crude 
measurements of patient-reported outcomes, as well as 
factors that may modify the how radiation cause late effects, 
compromise these possibilities. We lack details to provide 
parameters from dose-volume modelling to utilize the full 
potential of these new technologies. Concerning bowel 
health, current scoring systems of radiation-induced late 
gastrointestinal must be refined. Important socially 
invalidating symptoms are not scored. An example is 
unexpected defecation into clothing – not sensing the need to 
go to the toilet and a sudden defecation into clothing as if 
one were already on the toilet. We documented this 
symptom among 11 percent of gynecological-cancer 
survivors. Another example is frequent and uncontrolled 
noisy flatulence. Traditional scoring systems have scales that 
do not distinguish or clearly depict person-incidence (events 
per individual per time unit), intensity and duration. But, 
probably most important, as we learn that decreased bowel 
health depends on several different types of radiation-
induced illness, we understand that grouping symptoms from 
different illnesses together in a score compromises our ability 
to acquire knowledge for prevention or relief. We cannot 
disentangle these different radiation-induced illnesses when 
symptoms from several illnesses are grouped together in the 
data sets we retrieve. Clearly, new strategies are needed. In 
my talk, I will propose a scoring system based on the data 
indicating that the at least 28 radiotherapy-induced atomized 
late gastrointestinal symptoms derive from six distinct 
illnesses, that is, six sets of risk organs or mechanisms. We 
have data from around 1500 survivors supporting this 
position. As we accumulate data for each of these six 
illnesses, we can define parameters in dose-volume models 
built on patient-reported outcomes much better than we 
previously could. Possibly we can also learn how, by 
employing probiotics or dietary changes, we can influence 
the interplay between the gut flora and stem-cell renewal to 
counteract inflammatory processes that probably are 
important for several of the six illnesses. Moreover, the 
knowledge may stimulate development of mouse models in 
which we can test, for example, how different bacterial 
species influence radiation-induced inflammation in the 
rectal wall. In the talk, I will give preliminary results from 
the establishment of such a model. A simplified 
nomenclature could label the six illnesses as involving 
processes resulting in leakage-related symptoms, urgency-
related symptoms, constipation-related symptoms, symptoms 
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related to excessive mucus production, symptoms related 
excessive gas production gas and symptoms related excessive 
blood production. A modern scoring system should have two 
or more atomized symptoms related to each of the six 
illnesses and appropriate response scales for frequency, 
intensity and duration. 
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Anorectal toxicity is a relevant side effect of pelvic 
radiotherapy for rectal, anal, gynaecologic and prostate 
cancer. Toxicity can be scored objectively by the physician 
according to established systems such as the CTCAE 
classification. In recent years, patient-reported outcomes 
(PROs) have received increasing attention when evaluating 
acute toxicity as well as late effects of cancer treatment. 
These include information directly obtained from the patient 
on symptoms and impairment as well as on quality of life. 
This presentation will focus on validated instruments to 
measure PROs related to anorectal function, including 
quality-of-life questionnaires and organ modules, e. g. those 
developed by the EORTC Quality of Life Group, and symptom 
questionnaires e. g. to measure continence. Objective 
measurements to quantify anorectal function such as 
sphincter manometry and endoscopic scores will be 
reviewed. The relationship between PROs and objective 
function assessment with physician-rated toxicity will be 
addressed. The outcomes for the above endpoints in major 
trials of pelvic radiotherapy will be presented, with a focus 
on rectal cancer and the effects of treatment concepts 
including short-course radiotherapy and long-course 
chemoradiation. Finally, dose-volume constraints in pelvic 
radiotherapy treatment planning and potential effects of 
highly conformal techniques such as IMRT or VMAT on 
anorectal symptoms, function and quality of life will be 
examined. 
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Radiotherapy is a well recognozed curative treatment option 
for localized prostate cancer. Optimal tumor control rates 
can only be achieved with high local doses, associated with a 
considerable risk of rectal toxicity - regarded as dose-limiting 
toxicity. Apart from already widely adapted technical 
advances, as intensity-modulated radiation therapy and 
image-guided radiotherapy techniques, the application of 
spacers placed between the prostate and anterior rectal wall 
has been increasingly used in the last years.  
Biodegradable spacers, including hydrogel, hyaluronic acid, 
collagen or an implantable balloon can create the desired 
effect. They can be injected or inserted in a short procedure 
under transrectal ultrasound guidance via a transperineal 
approach. A distance of about 1.0-1.5cm is usually achieved 
between the prostate and rectum, excluding the rectal wall 
from the high isodoses. Several studies have shown well 
tolerated injection procedures and treatments. Apart from 
considerable reduction of rectal dose compared to 
radiotherapy without a spacer, clinical toxiciyt results are 
favourable. A prospective randomized trial demonstrated a 
reduction of rectal toxicity after hydrogel injection in men 
undergoing prostate image-guided intensity-modulated 
radiation therapy. The results are encouraging for continuing 
evaluation in dose escalation, hypofractionation, stereotactic 
radiotherapy or re-irradiation trials in the future. 
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Treatment planning systems (TPSs) are of high importance in 
modern brachytherapy. The users rely on the output of these 
special software; wrong calculations may result in severe 
patient harm. Thus it is necessary to systematically check 
these software programs. 
Many checks in TPSs are identical for high-dose-rate 
brachytherapy with afterloaders and low-dose-rate 
brachytherapy with seeds. But some differences exist, e.g. as 
checking of afterloader parameters.  
After the installation of the software the acceptance test is 
to be carried out. This test protocol is typically provided by 
the vendor and should be passed before further checking. In 
a second step the commissioning is carried out. In this 
procedure all clinical relevant data and properties of the TPS 
must be tested and reported. Examples for items to check 
are:  
- Afterloader characteristics (number of channels, min./max. 
channel lengths, max. allowed dwell time, …) 
- Source characteristics (nuclide, decay, …) 
- TG-43 consensus dataFor Model-based dose calculation 
algorithms, commissioning following TG-186 report 
- Applicator checks 
To ensure the consistency and data integrity of the TPS 
periodical tests should be performed after the 
commissioning. Important points are to validate the integrity 
of base parameters of the TG-43 data and the recalculation 
of patient treatment plans.  
Most TPSs offer inverse planning algorithms. The algorithm 
itself is often not fully transparent by the user, thus 
comparison with manual calculations is not practical. 
Nevertheless, the consistency of such planning technique can 
be checked by recalculation of a test plan using a constant 
parameter set. In addition to the tests above end-to-end 
tests can be performed to check the whole treatment chain, 
including imaging, TPS, afterloader, and data transfer. 
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In the past decade 3D image guided brachytherapy has been 
introduced into clinical practice worldwide. This enables 
conformation of the dose distribution to the target volume 
and avoidance of high dose to organs at risk (OAR) using CT, 
MR, and/or ultrasound (US) imaging. In such modern 
techniques sectional images give the relationship of the 
shape and the position of the applicator(s)/sources in 
relation to the anatomy of the patients. This means that the 
quality assurance (QA) programs also should include specific 
topics related to image quality additional to traditional 
procedures checking the source strengths and dose 
calculation issues. QA for image quality is well established in 
the area diagnostic and many of these procedures can be 
used also for brachytherapy. However, the procedures should 
be modified in order to reflect the conditions of use in 
brachytherapy compared to a diagnostic session.  
To optimise the image quality in diagnostic procedures 
dedicated phantom is often used. Various image quality 
parameters are tested by evaluation for example slice 
thickness, spatial resolution, uniformity and noise. In 
contrast to diagnostic imaging, the ability to reconstruct 
several points or a geometric structure with high accuracy is 
crucial in brachytherapy. Therefore, a procedure to check 
the geometric accuracy have to be included in a QA program. 
